Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Scientists probe strategies to repair neuron damage in multiple sclerosis.
XVI European Charcot Foundation lecture: nutrition and environment, can MS be prevented?
Early magnetic resonance imaging predictors of clinical progression after 48 months in clinically isolated syndrome patients treated with intramuscular interferon β-1a.
Epigenetics in multiple sclerosis susceptibility: difference in transgenerational risk localizes to the major histocompatibility complex.
Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination.
Remyelination in experimental models of toxin-induced demyelination.
Postpartum disease activity and breastfeeding in multiple sclerosis revisited.
Positive results from Phase 3 CONFIRM clinical trial show efficacy and safety of oral BG-12 in multiple sclerosis
No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis.
Natural recovery and protection from autoimmune encephalomyelitis: contribution of CD4+CD25+ regulatory cells within the central nervous system.
BG 12: BG 00012, BG 12/Oral Fumarate, FAG-201, second-generation fumarate derivative--Fumapharm/Biogen Idec.
Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder.
TECFIDERA® (dimethyl fumarate) approved in the European Union as a first-line oral treatment for multiple sclerosis
Genetics and the environment converge to dysregulate N-glycosylation in multiple sclerosis.
Zist Daru, ZIFERON
Parenteral Dilantin®
Population pharmacokinetics and pharmacodynamics of dalfampridine-ER in healthy volunteers and in patients with MS.
Mycophenolate mofetil therapy in the management of inflammatory bowel disease - A retrospective case series and review.
Vitamin D and disease activity in multiple sclerosis before and during interferon-β treatment.
The IFN-β 1b effect on Cu Zn superoxide dismutase (SOD1) in peripheral mononuclear blood cells of relapsing-remitting multiple sclerosis patients and in neuroblastoma SK-N-BE cells.
EAE: an immunologist's magic eye.
Treatment withdrawal in relapsing-remitting multiple sclerosis: a retrospective cohort study.
Treatment discontinuation and disease progression with injectable disease-modifying therapies: findings from the north american research committee on multiple sclerosis database.
Recruiting women smokers: the engineering of consent.
Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

Pages